Saturday 17 October 2026
Export INAB’s income statement to Excel — free account
IN8bio, Inc.
INAB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 79.8% and free cash flow fell 1.30%, each against the same quarter a year earlier.
1.11
0.08
−6.72%
Follow INAB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(189.72%) | (92.49%) | (103.55%) | (111.11%) | |
| (126.22%) | (73.05%) | (82.28%) | (90.80%) | ||
ROIC |
(513.16%) | (2,663.76%) | (1,448.44%) | (2,948.56%) | |
Return on Tangible Assets |
(169.77%) | (73.15%) | (85.78%) | (104.62%) | |
Free Cash Flow per Share |
(3.22) | (2.91) | (0.75) | (0.75) | |
Free Cash Flow |
(14.60) | (12.71) | (14.66) | (14.63) | |
Capital Expenditures |
— | — | (0.12) | (0.27) | |
| Other line items | |||||
Cash ROIC |
(60.98%) | (23.26%) | (32.78%) | (40.28%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.71 | 0.65 | 0.77 | 0.77 | |
Depreciation/Fixed assets |
1.28 | 1.35 | 1.44 | 1.25 | |
Capex/Depreciation |
0.00 | 0.00 | (0.05) | (0.14) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.22) | (2.91) | (0.75) | (0.74) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates